By Josh Beckerman
Shares of MeiraGTx Holdings shares reached a 52-week high after the company said 11 children treated to date in a drug study gained visual acuity after treatment.
The stock was recently up 9.1%, to $7.45, Friday after touching an intraday high of $7.80. Shares are up about 23% since the start of the year.
The genetic-medicines company reported results from a study of rAAV8.hRKp.AIPL1 in children who were legally blind at birth with AIPL1-associated severe retinal dystrophy.
A paper published in The Lancet presents data for the first four, who were treated unilaterally. Following the strong safety and substantial efficacy demonstrated in this cohort, another seven have now been treated bilaterally.
"With these truly exceptional results in hand, we are working with global regulators on expedited approval of rAAV8.hRKp.AIPL1 to provide access to babies born with AIPL1-related LCA4," the company said.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 21, 2025 14:41 ET (19:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.